Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Regina Broadband's Earnings Conference Call (B)
Powell, Elizabeth A.; Demers, Elizabeth A.Caso DARDEN-C-2368-EContabilidad y controlWithin 30 minutes of releasing its Q4 and year-end earnings, Regina Broadband’s stock was down by over 25%. The company’s CEO and CFO realized they needed to quickly reframe and sharpen the message they would be giving to Regina’s shareholders and investors during that afternoon’s conference call, scheduled to take place in 15 minutes.Desde 5,74 €
-
The Female Health Company (C)
Powell, Elizabeth A.; Yemen, GerryCaso DARDEN-BC-0253-EConocimiento y comunicaciónIt has been nearly 30 years since Mary Ann Leeper was almost ready to give up on the female condom (as described in the A case). By 2012, FHCO had built its brand and achievements on its global reach; Leeper and her colleagues had introduced the company’s second-generation female condom (FC2) in 138 countries. The company, which by now had 144 employees, found itself trying to succeed once more in the domestic U.S. market. This time around, they ...Desde 5,74 €
-
Abiomed and the AbioCor Clinical Trials (B)
Powell, Elizabeth A.; Goldberg, RebeccaCaso DARDEN-BC-0205-EConocimiento y comunicaciónIn late 2002, a sensational article in the New York Times depicting James Quinn's experience and death following implantation with the AbioCor artificial heart raises questions about Abiomed's handling of the informed consent process related to its clinical trials. At the same time, investor confidence in the company wanes due to the apparent stall in the clinical trial's progress. This B case illustrates Abiomed's handling of the situation, alon...Desde 5,74 €
-
Abiomed and the AbioCor Clinical Trials (A)
Powell, Elizabeth A.; Goldberg, RebeccaCaso DARDEN-BC-0204-EConocimiento y comunicaciónTo protect patient confidentiality, Abiomed, makers of the AbioCor artificial heart, adopt a 30-day "quiet period" surrounding implantations, which is construed by mainstream media as a "news blackout." In late 2002, James Quinn, the fifth transplant recipient, dies after 289 days. A month later, in a New York Times article describing Quinn's pain and suffering, Quinn's widow claims that her husband had not been adequately informed of the likely ...Desde 8,20 €